Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study

NCT05130073 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05130073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study
Lead sponsor
M.D. Anderson Cancer Center
Phase
Observational
Overall status
Completed
Start date
July 31, 2019
Completion date
December 14, 2023
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma, stage 0 anal cancer ajcc v8, stage i anal cancer ajcc v8, stage ii anal cancer ajcc v8, stage iia anal cancer ajcc v8, stage iib anal cancer ajcc v8, stage iii anal cancer ajcc v8, stage iiia anal cancer ajcc v8, stage iiib anal cancer ajcc v8, stage iiic anal cancer ajcc v8